New developments in the use of β-blockers for the management of heart failure

Bibliography

• EICHHORN EJ: Experience with I3-blockers in heart failure mortality trials. Clin. Cardiol (1999) 22 (Suppl. V):V21–V29.
   Google Scholar
• SALLACH JA, GOLDSTEIN S: Use of I3-blockers in congestive heart failure. Ann. Med. (2003) 35:259–266.
   PubMed Web of Science ®Google Scholar
• DURAND JB: Current guidelines in heart failure management. Ethn. Dis. (2002) 12 (Suppl. 1):S1-3-S 1-1 1.
   Google Scholar
• HORWICH TB, FONAROW GC: Prevention of heart failure. Curr: Cardiol Rep. (2002) 4:194–199.
   PubMedGoogle Scholar
• CESARIO DA, FONAROW GC: I3-blocker therapy for heart failure: the standard of care. Rev Cardiovasc. Med. (2002) 3:14–21.
   PubMedGoogle Scholar
• THOMAS JA, MARKS BH: Plasma norepinepherine in congestive heart failure. Am.! Cardiol (1978) 41(2):233–243.
   PubMed Web of Science ®Google Scholar
• COHN JN, LEVINE TB, OLIVARI MT et al.: Plasma norepinepherine as a guide to prognosis in patients with chronic congestive heart failure. N Engl. I Med. (1984) 311:819–823.
   PubMed Web of Science ®Google Scholar
• PACKER M, LEE WH, KESSLER PD et al.: Role of neurohormonal mechanisms in determining survival in patients with severe chronic heart failure. Circulation (1987) 75:IV80-1V92.
   Google Scholar
• NICHOLLS DP, ONUOHA GN, McDOWELL G et al.: Neuroendocrine changes in chronic cardiac failure. Basic Rex Cardiol (1996) 91 (Suppl. 1):13–20.
   Google Scholar
• HABER HL, CHRISTOPHER LS, GIMPLE LW et al: Why do patients with congestive heart failure tolerate the of I3-blocker therapy? Circulation (1993) 88: 1610-1619.
   Google Scholar
• BRISTOW MR: I3-adrenergic receptor blockade in chronic heart failure. Circulation (2000) 101:558–569.
   PubMed Web of Science ®Google Scholar
• BRISTOW MR, GINSBERG R, FOWLER M et al.: 131- and I32-adrenergic receptor subpopulations in normal and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective I31-receptor downregulation in heart failure. Circ. Res. (1986) 59:297–309.
   PubMed Web of Science ®Google Scholar
• BRISTOW MR: Changes in myocardial and vascular receptors in heart failure. J. Am. Coll. Cardiol (1993) 22(Suppl. A):61A–71A.
   Google Scholar
• BRODDE OE, SCHULER S, KRETSCH R et al.: Regional distribution of I3-adrenoceptors in the human heart: coexistence of functional 131- and 132-adrenoceptors in both atria and ventricles in severe congestive cardiomyopathy. Cardiovasc. Pharmacol (1986) 8:1235–1242.
   PubMed Web of Science ®Google Scholar
• MANN DL, KENT RL, PARSONS B et al.: Adrenergic effects on the biology of the adult mammalian cardiocyte. Circulation (1992) 85:790–804.
   PubMed Web of Science ®Google Scholar
• KRUM H, LIEW D: New developments in the pharmacological treatment of chronic heart failure. Expert Opin. Investig. Drugs (2003) 12:751–757.
   PubMed Web of Science ®Google Scholar
• KEATING GM, JARVIS B: Carvedilol. A review of its use in chronic heart failure. Drugs (2003) 63:1697–1741.
   Google Scholar
• GILBERT EM, OLSEN SL, DG et al.: I3-adrenergic receptor regulation and left ventricular function in idiopathic dilated cardiomyopathy. Am. J. Cardiol (1993) 71:23C–29C.
   Google Scholar
• NEWTON GE, PARKER JD: pi vs nonselective I3-blockade in human congestive heart failure: acute effects on cardiac sympathetic activity. Circulation (1995) 92:1-395 (Abstract).
   Google Scholar
• OLSEN SL, GILBERT EM, DG et al.: Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study. I Am. Coll. Cardiol (1995) 25:1225–1231.
   PubMed Web of Science ®Google Scholar
• YUE TL, HUNG-YUAN C, LYSKO PG et al.: Carvedilol, a new vasodilator and I3-adrenoceptor antagonist, is an antioxidant and free radical scavenger. Pharmacol Exp. Ther. (1992) 263:92–98.
   PubMed Web of Science ®Google Scholar
• FEUERSTEIN G, BRIL A, RR Jr: Protective effects of carvedilol in the myocardium. Am. (1997) 80:41L–45L.
   Google Scholar
• BOOK WM: Carvedilol: a nonselective I3-blocking agent with antioxidant properties. Congest. Heart Fail. (2002) 8:173–177.
   PubMedGoogle Scholar
• BRIL A, SLIVJAK M, DiMARTINO MJ et al.: Cardioprotective effects of carvedilol, a novel 13 adrenoceptor antagonist with vasodilating properties, in anaesthetised minipigs: comparison with propanolol. Cardiovasc. Res. (1992) 26:518–525.
   PubMed Web of Science ®Google Scholar
• DHALLA AK, SING N, SINGAL PK: Antioxidant therapy associated with the reversal of oxidative stress delays the pathogenesis of heart failure. Circulation (1994) 90:1-491 (Abstract).
   Google Scholar
• YUE TL, MA XL, WANG X et al: Possible involvement of stress-activated protein kinase signaling pathway and Fas receptor expression in prevention of ischemia/ reperfusion-induced cardiomyocyte apoptosis by carvedilol. Circ. Res. (1998) 82:166–174.
   PubMed Web of Science ®Google Scholar
• FEUERSTEIN G, YUE TL, MA X et al.: Novel mechanisms in the treatment of heart failure: inhibition of oxygen radicals and apoptosis by carvedilol. Prog. Cardiovasc. Dis. (1998a) 41(1 Suppl. 1):17–24.
   Google Scholar
• PACKER M, BRISTOW MR, COHN JN et al: The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl. I Med. (1996) 334:1349–1355.
   PubMed Web of Science ®Google Scholar
• ••Landmark study that showed a beneficial of a P-blocker, carvedilol, in the management of HE
   Google Scholar
• HAEUSLER G, SCHLIEP H-J, SCHELLING P et al.: High I31-selectivity and favourable pharmacokinetics as the outstanding properties of bisoprolol.. Phann. (1986) 8\(Suppl. 11):S2–S15.
   Google Scholar
• McGAVINJK, KEATING GM: Bisoprolol. A review of its use in chronic heart failure. Drugs (2002) 62:2677–2696.
   Google Scholar
• CIBIS-II INVESTIGATORS AND COMMITTEES: The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomised trial. Lancet (1999) 353:9–13.
   PubMed Web of Science ®Google Scholar
• BRISTOW MR, RODEN RL, LOWES BD & al: The role of third-generation 13-blocking agents in chronic heart failure. Clin. Cardiol. (1998) 21(Suppl. I):13–113.
   Google Scholar
• I3-BLOCKER EVALUATION OF SURVIVAL TRIAL INVESTIGATORS: A trial of the P-blocker bucindolol in patients with advanced chronic heart failure. N Engl. Med. (2001) 344:1659–1667.
   PubMedGoogle Scholar
• •Major clinical trial that did not show significant efficacy in HF and indicated that there are differences among P-blockers.
   Google Scholar
• ANDREKA P, AIYAR N, OLSON LC et al.: Bucindolol displays intrinsic sympathomimetic activity in human myocardium. Circulation (2002) 105:2429–2434.
   PubMed Web of Science ®Google Scholar
• MERIT-HF STUDY GROUP: Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet (1999) 353:2001–2017.
   PubMed Web of Science ®Google Scholar
• PRAKASH A, MARKHAM A: Metoprolol.A review of its use in chronic heart failure. Drugs (2000) 60:647–678.
   Google Scholar
• PACKER M, COATS AJ, FOWLER MB et al.: Effect of carvedilol on survival in chronic heart failure. N Engl. I Med. (2001) 344:1651–1658.
   PubMed Web of Science ®Google Scholar
• •Definitive clinical trial that showed efficacy of carvedilol in severe (NYHA class IV) HE
   Google Scholar
• DARGIE HJ, THE CAPRICORN STEERING COMMITTEE: Design and methodology of the CAPRICORN trial - a randomised double blind placebo controlled study of the impact of carvedilol on morbidity and mortality in patients with left ventricular dysfunction after myocardial infarction. Eur: J. Heart Fail (2000) 2:325–332.
   PubMed Web of Science ®Google Scholar
• DARGIE HJ, THE CAPRICORN INVESTIGATORS: Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet (2001) 357:1385–1390.
   PubMed Web of Science ®Google Scholar
• DOUGHTY RN, WHALLEY GA, WALSH HA et al.: Effects of carvedilol on left ventricular remodeling after acute myocardial infarction. The CAPRICORN echo study. Circulation (2004) 109:201–206.
   PubMed Web of Science ®Google Scholar
• REMME WJ, THE CARMEN STEERING COMMITTEE AND INVESTIGATORS: The carvedilol and ACE-inhibitor remodelling mild heart failure evaluation trial (CARMEN) - rationale and design. Cardiovasc. Drugs Thec (2001) 15:69–77.
   PubMed Web of Science ®Google Scholar
• REMME WJ, REIGGER G, P et al.: The benefits of early combination treatment of carvedilol and an ACE-inhibitor in mild heart failure and left ventricular systolic dysfunction. The carvedilol and ACE-inhibitor remodelling mild heart failure evaluation trial (CARMEN). Cardiovasc. Drugs Ther. (2004) 18:57–66.
   Google Scholar
• POOLE-WILSON PA, CLELAND JGF, DI LENARDA A et al.: Rationale and design of the carvedilol or metoprolol European trial in patients with chronic heart failure: COMET. Ear: I Heart Fail (2002) 4:321–329.
   Google Scholar
• POOLE-WILSON PA, SWEDBERG K, CLELAND JG et al: Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomized controlled trial. Lancet (2003) 362:7–13.
   PubMed Web of Science ®Google Scholar
• PACKER M, ANTONOPOULAS GV, BERLIN JA et al: Comparative effects of and metoprolol on left ventricular ejection fraction in heart failure: results of a meta-analysis. Am. Heart 1. (2001) 141:899–907.
   PubMed Web of Science ®Google Scholar
• ••Landmark clinical trial that directlycompared carvedilol and metoprolol in HE
   Google Scholar
• DOUGHTY RN: P-blocker therapy in heart failure. Heart Fail. Mont. (2000) 1:2–7.
   PubMedGoogle Scholar
• CLELAND JGF: 13-blockers for heart failure: why, which, when, and where. Med. Clin. N Am. (2003) 87:339–371.
   PubMed Web of Science ®Google Scholar
• JACOB S, RETT K, WICKLMAYR M et al.: Differential effect of chronic treatment with two 13-blocking agents on insulin sensitivity: the carvedilol-metoprolol study. Hyper. (1996) 14:489–494.
   Web of Science ®Google Scholar
• GIUGLIANO D, ACAMPORA R, MARFELLA R et al: Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension: a randomized, controlled trial. Ann. Intern. Med. (1997) 126:955–959.
   PubMed Web of Science ®Google Scholar
• BOTTCHER M, REFSGAARD J, GOTZSCHE 0 et al.: Effect of carvedilol on microcirculatory and glucose metabolic regulation in patients with congestive heart failure secondary to ischemic cardiomyopathy. Am. I Cardiol. (2002) 89:1388–1393.
   Google Scholar
• REFSGAARD J, THOMSEN C, ANDREASEN F et al.: Carvedilol does not alter the insulin sensitivity in patients with congestive heart failure. Eui: I Heart Fail. (2002) 4:445–453.
   PubMed Web of Science ®Google Scholar
• COLETTA AP, CLARK AL, A-M et al.: Clinical trials update from the European Society of Cardiology heart failure meeting: COMET, COMPANION, Tezosentan and SHAPE. Ear.' Heart Fail (2003) 5:545–548.
   PubMed Web of Science ®Google Scholar
• FEUERSTEIN G, LIU GL, YUE TL et al: Comparison of metoprolol and carvedilol pharmacology and cardioprotection in rabbit ischemia and reperfusion model. Eui:. (1998) 351:341–350.
   PubMed Web of Science ®Google Scholar